Kawakami, Takeshi http://orcid.org/0000-0001-9385-9516
Mizusawa, Junki
Hasegawa, Hiroko
Imazeki, Hiroshi
Kano, Kazuki
Sato, Yuya
Iwasa, Satoru
Takiguchi, Shuji
Kurokawa, Yukinori
Doki, Yuichiro
Boku, Narikazu
Yoshikawa, Takaki
Terashima, Masanori
Funding for this research was provided by:
the National Cancer Center Research and Development Funds (20S-3, 23-A-16, 23-A-19, 26-A-4, 29-A-3, 2020-J-3)
AMED (JP16ck0106048)
Article History
Received: 16 April 2022
Accepted: 4 June 2022
First Online: 29 June 2022
Declarations
:
: Takeshi Kawakami received honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, and Bristol-Myers Squibb. Junki Mizusawa received National Cancer Center Research and Development Funds and Japan Agency for Medical Research and Development via his institution and honoraria from Taiho Pharmaceutical and Chugai Pharmaceutical. Satoru Iwasa received research funding from Taiho Pharmaceutical via his institution and honoraria from Taiho Pharmaceutical. Narikazu Boku received grants from Ono Pharmaceutical and Takeda Pharmaceutical, honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, and Daiichi-Sankyo. Yuichiro Doki received honoraria from Taiho Pharmaceutical. Takaki Yoshikawa received lecture fee from Taiho Pharmaceutical. Yukinori Kurokawa received lecture fee from Taiho Pharmaceutical. Masanori Terashima received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Yakult Honsha, Takeda Pharmaceutical, Pfizer Japan, Astra-Zeneca, Daiichi-Sankyo, Johnson and Johnson, Medtronic Japan, Intuitive Japan, and Olympus. The other authors declare that they have no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.